The association of SF3B1 mutations with lower monocyte surface HLA-DR expression identified here may be of clinical relevance, for example in view of the predicted poor response of SF3B1mut MDS to IST [6, 7]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.